Valve repair versus valve replacement for degenerative mitral valve disease  by Gillinov, A. Marc et al.
Gillinov et al Surgery for Acquired Cardiovascular DiseaseValve repair versus valve replacement for degenerative
mitral valve disease
A. Marc Gillinov, MD,a Eugene H. Blackstone, MD,a,b Edward R. Nowicki, MD,a Worawong Slisatkorn, MD,a
Ghannam Al-Dossari, MD,a Douglas R. Johnston, MD,a Kristopher M. George, MD,a Penny L. Houghtaling, MS,b
Brian Griffin, MD,c Joseph F. Sabik, III, MD,a and Lars G. Svensson, MD, PhDaA
CDSupplemental material is
available online.
Objective: The study objective was to identify characteristics differentiating patients
undergoing valve replacement versus valve repair for degenerativemitral valve disease
and to use this information to compare survival and reoperation after each procedure.
Methods: From 1985 to 2005, 3286 patients underwent isolated primary operation for
degenerative mitral valve disease. Valve repair was performed in 3051 patients (93%),
and valve replacement was performed in 235 patients (7.2%). A propensity model and
score developed for fair comparison of outcomes yielded 195 matched pairs.
Results: Patients undergoing replacement were older (706 12 years vs 576 13 years)
and had more complex valvar pathology, symptoms, and left ventricular dysfunction.
Thus, the characteristics of the propensity-matched patients undergoing repair more
resembled those of the patients undergoing replacement (older, complex valvar pa-
thology) than patients undergoing typical repair. Eight patients died in the hospital
(0.26%) after repair and 5 patients (2.1%) died after replacement (P 5 .001). Unad-
justed survival at 5, 10, and 15 years was 95%, 87%, and 68% after repair and
80%, 60%, and 44% after replacement, respectively (P , .0001); however, among
propensity-matched patients, survival was similar (P 5 .8): 86% versus 83% at 5
years, 63% versus 62% at 10 years, and 43% versus 48% at 15 years. Freedom
from reoperation among propensity-matched patients was 94% at 5 and 10 years after
repair and 95% and 92% at 5 and 10 years after replacement, respectively (P 5 .6).
Conclusion: It is reasonable to perform valve repair in elderly patients with complex
degenerative mitral valve pathology because it can eliminate the need for anticoagu-
lation and risk of prosthesis-related complications. However, when valve pathology is
so complex that repair is infeasible, this study demonstrates that valve replacement
does not diminish long-term outcomes.
T
he reported advantages of mitral valve repair over mitral valve replacement in-
clude preservation of left ventricular function; greater freedoms from endocar-
ditis, thromboembolism, and anticoagulant-related hemorrhage; and, most
important, improved survival.1-5 For these reasons, valve repair is preferred to valve
replacement in patients with degenerative mitral valve disease.6 However, there are
few data available to clarify the relative effects of patient factors and choice of valve
procedure (repair vs replacement) on outcome after surgery for mitral regurgitation
(MR) caused by degenerative disease. Selected patients with rheumatic and ischemic
MR seem to have equal, and in some cases better, survival with valve replacement as
with valve repair, illustrating the importance of patient characteristics on outcome.7,8
In patients with degenerative MR, we sought to 1) identify characteristics differenti-
ating those undergoing valve replacement from those undergoing valve repair, 2) use
this information to compare, among matched patients, survival and reoperation after
each procedure, and 3) contrast these outcomes with those of typical patients under-
going valve repair.
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CDAbbreviation and Acronym
MR 5 mitral regurgitation
Materials and Methods
Study Population
From January of 1985 to January of 2005, 3286 patients with iso-
lated degenerative mitral valve disease underwent surgery for MR.
Repair was performed in 3051 patients (93%), and replacement
was performed in 235 patients (7%). Sixty-four patients had unsuc-
cessful repair that was converted to replacement during the initial
operation; for the main treatment-received analyses, these patients
were considered to be in the replacement group, and for secondary
analyses of crossover to replacement, these patients were considered
to be in the repair group (intent to treat). Patients having concomitant
coronary artery bypass grafting, aortic valve disease, hypertrophic
cardiomyopathy, or ascending aortic aneurysm were excluded.
The results in subsets of these patients have been reported.1 Con-
comitant tricuspid valve repair for functional tricuspid regurgitation
was performed in 171 patients (5.2%), and ablation of atrial fibrilla-
tion was performed in 153 patients (4.6%).
Preoperative MR was graded by echocardiography using stan-
dard techniques; all patients had moderately severe (31, 8.2%) or
severe (41, 92%)MR. Data were extracted from the Cardiovascular
Information Registry, a repository of extensive clinical and surgical
data entered concurrently with patient care. Use of these data for re-
search was approved by the institutional review board, with patient
consent waived.
Surgical Technique
Surgical approach wasminimally invasive in 1726 patients, full ster-
notomy in 1552 patients, and right thoracotomy in 4 patients. The
minimally invasive technique included a 6- to 8-cm skin incision
and partial upper sternotomy.9 The most common repair techniques
included posterior leaflet resection with (1244) or without (1466)
sliding repair and chordal transfer (423). Anuloplasty techniques in-
cluded Cosgrove-Edwards anuloplasty band (Edwards Lifesciences
LLC, Irvine, Calif) (2254, 74%), Carpentier-Edwards classic ring
(Edwards Lifesciences LLC) (411, 13%), and posterior bovine peri-
cardial strip (296, 9.7%); 90 patients (2.9%) had leaflet repair with-
out anuloplasty. Among 235 patients undergoing mitral valve
replacement, prostheses were bioprosthetic in 179 (76%) and me-
chanical in 56 (24%). At mitral valve replacement, the posterior leaf-
let and its attached subvalvar apparatus were routinely preserved;
the anterior leaflet generally was excised.
Follow-up
Patients were followed routinely at 2, 5, 10, 15, and 20 years. At
each follow-up, patients were contacted by mailed institutional
review board-approved questionnaire or telephone interview, with
patient consent. Follow-up for mitral valve reoperation depended
entirely on this active follow-up. Of the 3286 patients, 897 were
not yet due for follow-up. Of the remaining 2389 patients, 303
(13%) were considered lost to follow-up (269 US and 29 foreign pa-
tients were untraced, and 5 patients did not consent to follow-up).
The median active follow-up was 2.6 years, with 25% followed886 The Journal of Thoracic and Cardiovascular Surgery c Aprilmore than 5.6 years, 10% followed $ 10 years, and 3% followed
$ 12 years; 11,689 patient-years of data were available for analyses
of reoperation. Information on vital status was supplemented by data
from the Social Security Death Index10,11 (cross-sectional passive
follow-up), yielding a total of 18,244 patient-years of data for anal-
ysis. Passive follow-up averaged 5.66 4.4 years, with 15% of living
patients followed $ 10 years and 5% followed $ 14 years. Graphs
of reoperation were truncated at 12 years, and graphs of survival
were truncated at 14 years.
Data Analysis
Factors Associated With Mitral Valve Replacement Versus Re-
pair. Multivariable logistic regression was performed to identify
factors associated with mitral valve replacement versus repair. Vari-
ables considered are listed in Appendix 1. Bagging was the method
for variable selection, with automated analysis of 500 resampled
data sets, followed by tabulating the frequency of occurrence at
P # .05 of both single factors and closely related clusters of fac-
tors.10,11 Factors with occurrence of 50% or more were retained in
the model.
Time-related Events. Nonparametric time-to-event estimates
were obtained by the Kaplan–Meier method. For mortality, a para-
metric method was used to resolve the number of phases of instanta-
neous risk (hazard function) and estimate shaping parameters.12 (For
additional details, see http://www.clevelandclinic.org/heartcenter/
hazard.) Thereafter, multivariable analyses were performed in
the hazard function domain. Variable selection used bagging, as
described earlier.
Outcomes in Propensity-matched Pairs. Because the character-
istics of patients receiving mitral valve replacement rather than re-
pair were different (Table 1), propensity score methods were used
to reduce selection bias in comparing outcomes.13,14 First, logistic
regression analysis was used to identify risk factors for valve re-
placement rather than repair, using bagging as described earlier in
the text. Second, this parsimonious model was amplified by nonstat-
istically significant variables representing every class of variable
available, 28 in all. Third, by using the resulting propensity model,
a propensity score representing the probability of having a replace-
ment was estimated for each patient (Figure E1). Fourth, on the basis
of the propensity scores, 195 matched pairs were identified.15
Finally, time-related outcomes were compared between matched
patients receiving repair and patients receiving replacement.
Survival in Unmatched Patients. Of 235 patients receiving re-
placement, 40 (17%) could not be matched to 1 of the 3051 patients
undergoing repair because the distribution of propensity scores for
the majority of those receiving repair was distinctively different
from that of those receiving replacement (Figure E1). Thus, we pres-
ent the characteristics and survival of unmatched patients in both
groups.14
Accounting for Attempted Repairs. The influence of attempted
valve repair, converted to replacement in the same operation, was
assessed in 2 ways. First, among propensity-matched pairs, the vari-
able ‘‘attempted repair’’ (crossover from repair to replacement in
same operative session) was added to the multivariable survival
model used to compare valve repair versus replacement. Second,
matched patients were compared as strictly intent-to-treat.
Presentation. Mortality, survival, and freedom from reoperation
estimates are accompanied by asymmetric 68% confidence limits
equivalent to 6 1 standard error. Categoric data are summarized2008
Gillinov et al Surgery for Acquired Cardiovascular DiseaseTABLE 1. Characteristics of patients undergoing mitral repair versus replacement
MV repair MV replacement
Characteristic n* No. (%) n* No. (%) P
Demography
Women 3051 966 (32) 235 116 (49) ,.0001
Age (y) 3051 57 6 13 235 70 6 11 ,.0001
Symptoms
NYHA class 3051 235 ,.0001
I 885 (29) 34 (14)
II 1741 (57) 133 (57)
III 369 (12) 61 (26)
IV 56 (1.8) 7 (3.0)
Mitral valve pathophysiology
MV prolapse 3051 235 ,.0001
Posterior 2530 (83) 100 (43)
Anterior 233 (7.6) 52 (22)
Bileaflet 288 (9.4) 83 (35)
MV calcification 3051 671 (22) 235 112 (48) ,.0001
Cardiac structure and function
LA diameter (cm) 2564 4.9 6 0.91 185 5.3 6 1.02 ,.0001
LVEF (echocardiogram, %) 2291 58 6 7.5 169 56 6 8.3 .0005
LV inner diameter in diastole (cm) 2664 5.8 6 0.81 188 5.6 6 0.93 .0008
LV inner diameter in systole (cm) 2650 3.5 6 0.75 188 3.4 6 0.86 .7
Posterior wall thickness (cm) 2593 1.1 6 0.19 189 1.2 6 0.21 ,.0001
Comorbidity
Atrial fibrillation/flutter 3051 475 (16) 235 78 (33) ,.0001
PAD 2864 200 (7.0) 208 38 (18) ,.0001
COPD 2216 290 (13) 150 36 (24) .0002
Hypertension 2938 1055 (36) 227 104 (46) .003
Treated diabetes 2952 44 (1.5) 233 9 (3.9) .006
Stroke 3051 61 (2.0) 235 13 (5.5) .0004
COPD, Chronic obstructive pulmonary disease; LV, left ventricular; LA, left atrial; LVEF, left ventricular ejection fraction;MV, mitral valve;NYHA, New York Heart
Association; PAD, peripheral arterial disease. *Data available.A
CDby frequencies and percentages, and continuous variables are sum-
marized by means 6 1 standard deviation.
Results
Factors Associated With Replacement Versus Repair
The probability of performing mitral valve repair rather than
replacement increased during the first few years of this expe-
rience, stabilizing at approximately 95% during the last 15
years (Figure 1, A). Patients undergoing replacement were
older (70 6 12 years vs 57 6 13 years, Figure 1, B) and
had more advanced symptoms, with 29% showing New
York Heart Association functional class III or IV versus
14% of patients undergoing repair (Table 1). Advanced
age, mitral valve calcification, anterior or bileaflet prolapse,
operation earlier in the experience, and surgeon identity
were associated with an increased probability of replacement
rather than repair (Table 2). These characteristics of patients
undergoing valve replacement were not typical of most
patients presenting for management of degenerative mitral
valve disease, as illustrated by the more favorable profile of
unmatched patients undergoing repair (Table 3).The Journal of ThoraOverall Survival
There were 13 hospital deaths (0.4%), 8 in patients undergo-
ing repair (0.26%; confidence limit 0.17%–0.39%) and 5 in
patients undergoing replacement (2.1%, confidence limit
1.2%%–3.5%) (P 5 .001). Unadjusted survival estimates at
1, 5, 10, and 15 years were 98%, 95%, 87%, and 68% after
repair and 92%, 80%, 60%, and 44% after replacement,
respectively (P , .0001). For patients undergoing repair,
survival was superior to that of an age-sex–matched US pop-
ulation; for patients undergoing replacement, survival was
equivalent to the matched US population after an initial
high-risk phase postoperatively (Figure 2).
Survival in Propensity-matched Patients
Among propensity-matched pairs, survival was similar after
both replacement and repair (P 5 .9; Figure 3). This finding
was corroborated by propensity-adjusted multivariable anal-
ysis (Table E1). Among these propensity-matched groups,
survival was similar to that of the age and sex-matched US
population after a period of higher risk early after operation
in both groups.cic and Cardiovascular Surgery c Volume 135, Number 4 887
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Survival was greater in patients undergoing repair who could
not be matched to patients undergoing replacement (Fig-
ure 4); these represent typical patients undergoing repair (Ta-
ble 3): young with no or mild symptoms, generally in sinus
rhythm, and having isolated posterior leaflet prolapse without
valve calcification. Survival was lowest in unmatched pa-
tients undergoing replacement, who were older (75 6 8.1
years), were more symptomatic, were more likely to be in
atrial fibrillation and have noncardiac comorbidities, and
rarely had isolated posterior mitral leaflet prolapse (7.5%),
but rather anterior or bileaflet prolapse and mitral valve cal-
cification. These comparisons were similar by multivariable
analysis of attempted repair (P . .5, Table E1) and intent-
to-treat analyses (P . .6).
Freedom from Reoperation
Among propensity-matched patients, there were 21 mitral
valve reoperations, 10 in the repair group and 11 in the re-
Figure 1. Factors associated with mitral valve repair versus re-
placement. Raw grouped frequencies (closed circles) and trend
(solid line). A, Time trend for mitral valve repair. B, Age trend for
mitral valve repair.888 The Journal of Thoracic and Cardiovascular Surgery c Apriplacement group (8/144 who received a bioprosthetic and
3/51 who received a mechanical prosthesis). Actuarial free-




In an institution where mitral valve repair is distinctly pre-
ferred, patients undergoing valve replacement rather than re-
pair for degenerative MR are older and sicker, with complex
mitral valve pathology and multiple comorbidities. Both
groups, however, experienced long-term survival commen-
surate with that of the general population. At this end of
the spectrum, survival and freedom from mitral valve reoper-
ation were similar after repair or replacement, including a
period of higher early postoperative risk.
Factors Associated With Mitral Valve Replacement
versus Repair
The primary objective of this study was to determine the
impact of mitral valve repair versus replacement on survival
and reoperation in patients with degenerative disease. How-
ever, examination of the data revealed important differences
between these patient groups. Patients undergoing valve
replacement were more likely to have complex valvar
pathology, including calcification and anterior or bileaflet
prolapse; these factors increase the difficulty of valve repair.
Although most replacements occurred in this group, our data
also demonstrate that the majority of such valves are repair-
able, and previous studies document excellent long-term du-
rability after repair.2,3,16,17 Patients with this complex valvar
pathology represent a distinct subgroup of those presenting
for surgical management of degenerative mitral valve dis-
ease; they are older and have more symptoms and comorbid-
ities, including atrial fibrillation for which they are already
TABLE 2. Factors associated with type of mitral valve
surgery




Older age 1 .26 6 0.111 ,.0001 100
Anterior or bileaflet prolapse 2.1 6 0.178 ,.0001 82
MV calcification 1 .09 6 0.173 ,.0001 90
Surgeon A 2.2 6 0.56 ,.0001 58
Surgeon B 2.1 6 0.38 ,.0001 83




20.033 6 0.0162 .04 65
Surgeon D 21.44 6 0.179 ,.0001 99
MV, Mitral valve; SE, standard error. *Percent of occurrences in 500
bootstrap models.l 2008
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MV repair MV replacement
Characteristic Unmatched (n 5 2856) Matched (n 5 195) Matched (n 5 195) Unmatched (n 5 40)
Demography
Women 869 (30) 97 (50) 91 (47) 25 (62)
Age (y) 56 6 12 69 6 10 69 6 11 75 6 8.1
Symptoms
NYHA class
I 859 (30) 26 (13) 30 (15) 4 (10)
II 1629 (57) 112 (57) 112 (57) 21 (52)
III 318 (11) 51 (26) 47 (24) 14 (35)
IV 50 (1.7) 6 (3.1) 6 (3.1) 1 (2.5)
Mitral valve pathophysiology
MV prolapse
Posterior 2435 (85) 95 (49) 97 (50) 3 (7.5)
Anterior 190 (6.6) 43 (22) 37 (19) 15 (37)
Bileaflet 231 (8.1) 57 (29) 61 (31) 22 (55)
MV calcification 582 (20) 89 (46) 88 (45) 24 (60)
Cardiac structure and function
LA diameter (cm) 4.9 6 0.91 5.2 6 0.92 5.3 6 1.05 5.2 6 0.87
LVEF (echocardiogram, %) 58 6 7.4 55 6 8.5 55 6 8.8 55 6 5.8
LV inner diameter in diastole (cm) 5.8 6 0.80 5.6 6 0.87 5.7 6 0.89 5.2 6 1.04
LV inner diameter in systole (cm) 3.5 6 0.74 3.4 6 0.85 3.5 6 0.84 3.2 6 0.90
Posterior wall thickness (cm) 1.10 6 0.190 1.12 6 0.20 1.2 6 0.21 1.13 6 0.190
Comorbidity
Atrial fibrillation/flutter 410 (14) 65 (33) 60 (31) 18 (45)
PAD* 165/2701 (6.1) 35/163 (21) 29/175 (17) 9/33 (27)
COPD 267/2095 (13) 23/121 (19) 27/121 (22) 9/29 (31)
Hypertension 974/2751 (35) 81/187 (43) 83/187 (44) 21 (52)
Treated diabetes 38/2763 (1.4) 6/189 (3.2) 5/193 (2.6) 4 (10)
Stroke 50 (1.7) 11 (5.6) 9 (4.6) 4 (10)
COPD, Chronic obstructive pulmonary disease; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection fraction;MV, mitral valve;NYHA, New York Heart
Association; PAD, peripheral arterial disease. *Denominator represents the number of observations for which values for variables were available.A
CDreceiving warfarin, and more likely to have left ventricular
dysfunction, as previously shown by David and colleagues.3
It is only in these patients that we could compare outcomes
after mitral valve repair and replacement. In particular, our
data do not enable comparison of outcomes after valve repair
versus replacement in the typical young patient in sinus
rhythm with isolated posterior leaflet prolapse, few symp-
toms, and no comorbidity, because few patients with this pro-
file undergo replacement at our institution.
The wide disparity of characteristics of patients undergo-
ing repair and replacement, particularly in settings such as
ours that are committed to repair, calls into question unad-
justed comparisons of outcomes after surgery for degenera-
tive mitral valve disease.2,4,18,19 For example, analyzing
1411 patients with mitral valve prolapse undergoing repair
(83%) or replacement (17%), Suri and colleagues focused
on the site of prolapse and claimed to demonstrate a survival
benefit of repair over replacement in patients with isolated
posterior or bileaflet prolapse.2 Patients in that study were
older andmore symptomatic than the typical patient undergo-The Journal of Thoring valve repair, and many also had coronary artery disease.
The presence of coronary artery disease introduces complex
confounding of results, complicating analyses.20 Risk-ad-
justed comparison of repair and replacement in that setting
indicated that repair usually (89%) conferred a survival
advantage.21
Mitral Repair versus Replacement: Outcomes
Surgical correction of degenerative MR, whether by repair or
replacement, was associated with long-term survival either
better than (repair) or similar to (replacement) that of the gen-
eral US population. Although unadjusted survival was better
after repair than replacement, propensity-matched groups
undergoing repair and replacement had similar survival
and freedom from reoperation. This finding does not negate
the generally accepted tenet that mitral valve repair is pref-
erable to replacement in most patients with degenerative
mitral valve disease and has excellent long-term durabil-
ity.1-6 Rather, these data enhance our understanding of
the roles of mitral valve repair and replacement in theacic and Cardiovascular Surgery c Volume 135, Number 4 889
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CDFigure 4. Survival in propensity-matched patients having repair
(blue) or replacement (red) compared with unmatched patients
having repair (orange) or replacement (black). Format is as in
Figure 2.
Figure 2. Unadjusted survival after mitral valve repair (blue) or
replacement (red) compared with age and sex-matched US pop-
ulation (dot-dash curves). Each symbol represents a death, and
vertical bars are 68% actuarial confidence limits. Numbers in pa-
rentheses represent patients remaining at risk. Solid lines are
parametric survival estimates enclosed within dashed 68% confi-
dence limits.subgroup of patients with complex valvar pathology. When
a valve either appears unrepairable or attempts to repair
fail, neither survival nor reoperation is adversely affected
by replacement.
Limitations
This is a single-institution study of operations performed dur-
ing a 20-year time span. However, repair techniques have re-
mained nearly constant, and valve replacement has included
chordal sparing since the late 1980s. This study addresses
survival and, to a lesser extent, reoperation after surgery for
degenerative mitral valve disease; we did not seek to examine
effects of mitral procedure on other outcomes, such as free-
dom from prosthesis-related morbidity.
Figure 3. Survival in propensity-matched patients having repair
(blue) or replacement (red) compared with age-sex–matched US
population (green). Format is as in Figure 2.890 The Journal of Thoracic and Cardiovascular Surgery c ApThis is not a randomized trial. At this point in the history
of mitral valve surgery, such a trial involving patients with
typical degenerative disease is likely infeasible. Rather, the
choice of surgical procedure and its conduct were surgeon-
dependent; for this reason, surgeon identity was included in
the analyses. This revealed that even in our institution
some surgeons are somewhat more likely than others to elect
valve replacement over valve repair.
The small number of valve replacements among typical
younger patients with degenerative disease prohibited assess-
ing the effect of repair versus replacement in that group.
Therefore, comparative survival analyses may apply only
Figure 5. Reoperation in propensity-matched patients after mitral
valve repair (blue), replacement with bioprosthetic valve (red), or
replacement with mechanical valve (black). Format of actuarial
estimates is as in Figure 2.ril 2008
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CDto patients with complex valvar pathology, who tend to be
older and have greater comorbidity.
Conclusions
Mitral valve repair is the procedure of choice for patients with
isolated degenerative valve disease, most of whom will be
relatively young, at most mildly symptomatic, and in sinus
rhythm with well-preserved left ventricular function and
only posterior leaflet prolapse. Mitral valve repair preserves
the native valve, has excellent durability, and spares the
patient from known adverse events of prosthetic heart valves.
It is reasonable to also consider valve repair in elderly
patients and in those with complex prolapse and valvar calci-
fication, particularly those in sinus rhythm, because this can
eliminate the need for anticoagulation and risk of prosthesis-
related complications. If such a patient is also in atrial fibril-
lation, we now recommend mitral valve repair plus surgical
ablation of atrial fibrillation.22 However, when valvar pathol-
ogy is so severe that repair is infeasible, valve replacement
does not diminish long-term survival.
The authors thank Songhua Lin, MS, for statistical program-
ming; Karen Mrazeck, Deborah Gladish, Tanya Ashinhurst, Wanda
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Appendix 1. Variables used in multivariable analyses
Demography
Age (y), sex, height (cm), weight (kg), body surface area
(m2), body mass index (kg/m22)
Preoperative Status
New York Heart Association functional class, Canadian an-
gina class, emergency operation
Mitral Valve Pathology
Leaflet prolapse (posterior, anterior, bileaflet), valve fibrosis
or thickening, valve calcification, elongated chordae (poste-
rior, anterior), chordal rupture (posterior, anterior), elongated
papillary muscle, dilatation of mitral anulus, dilated left ven-
tricle, regurgitation grade (0 to 41 scale), left atrial diameter,
and volume
Left Ventricular Structure and Function
LV mass (g/m22), LV inner diameter in diastole (cm), LV
end-diastolic volume (mL), LV inner diameter in systoleacic and Cardiovascular Surgery c Volume 135, Number 4 891
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Dr T. David (Toronto, Canada). This is another thought-provoking
study from the Cleveland Clinic surgeons. I have to confess that
when I first read the abstract last January, I questioned the validity
of the conclusion and immediately asked our statistician to analyze
our data on mitral valve surgery for MR due to degenerative disease.
I had always believed that mitral valve repair was better than mitral
valve replacement because of the importance of the mitral valve ap-
paratus in left ventricular function. Moreover, prosthetic valves are
far from perfect, and conventional wisdom is that they are associated
with a higher risk of valve-related mortality and morbidity than
valve repair.
Much to my disappointment, our statistician gave me some bad
news: Our clinical outcomes as far as survival was concerned were
identical to yours. Overall, patients who had mitral valve repair had
better long-term survival than patients who had mitral valve replace-
ment, but the 2 groups of patients were different, and when matched
by propensity score analysis, the difference in survival disappeared.
In other words, mitral valve repair did not enhance lifespan when
compared with mitral valve replacement in matched patients. How-
(cm), LV end-systolic volume (mL), posterior wall thickness
(cm), intraventricular septal thickness (cm), LV relative wall
thickness, LV dysfunction grade (0 5 none, 1 5 mild, 2 5
moderate, 3 5 severe), previous myocardial infarction, LV
ejection fraction (%)
Other Cardiac Comorbidity
Atrial fibrillation, coronary artery stenosis ($50%, any) (left
main trunk, left anterior descending coronary artery, circum-
flex coronary artery, right coronary artery), number of coro-
nary systems with . 50% stenosis, family history of
coronary artery disease, ventricular arrhythmia, complete
heart block, history of endocarditis, history of heart failure
Noncardiac Comorbidity
History of hypertension, treated diabetes (insulin treated/not
insulin treated), stroke, smoking; peripheral arterial disease,
chronic obstructive pulmonary disease, renal failure, blood
urea nitrogen (mg/dL21), creatinine (mg/dL21), bilirubin
(mg/dL21), cholesterol (mg/dL21) (total, high-density lipo-
protein, low-density lipoprotein), triglycerides (mg/dL21),
hematocrit (%)
Details of Procedure
Surgical approach (minimally invasive), mitral valve repair
details (posterior/anterior/bileaflet repair, leaflet resection,
sliding leaflet repair, chordal resection, cleft repair, leaflet su-
ture, leaflet debridement, type of anuloplasty ring), mitral
valve replacement details (mechanical or bioprosthetic, pro-
pensity for replacement), tricuspid valve repair
Experience
Date of operation, surgeon
LV, Left ventricular.892 The Journal of Thoracic and Cardiovascular Surgery c Apever, as in your study, the matched patients were older, had more
advanced functional classes, and had more comorbid conditions.
I remain puzzled with these results, but that is what your and our
data showed.
I had hoped to challenge your results, but I can’t. All I can ask
you is to speculate on what would the results be if we compared
the outcomes of valve repair with replacement in younger, mini-
mally symptomatic, low-risk patients, such as most that we now op-
erate on? Also, did you determine the predictors of survival in all
patients by multivariable analysis? If so, was mitral valve repair
an independent predictor of survival?
Dr Gillinov. As to the first question, this relates to our precon-
ceived notions and to beliefs about mitral valve repair that we
hold dear. We still believe that mitral valve repair is the procedure
of choice for degenerative disease. We do not have enough younger
patients with posterior prolapse who received replacement to com-
pare repair and replacement in that group. However, the mean age
of those patients is 57 years, and I have to think that if we put a me-
chanical valve or a bioprosthesis in a 57-year-old, that person will be
facing a quarter century of risk for prosthesis-related morbidity;
I believe that repair reduces these risks. Our hope and speculation
are that to have a valve repair for 25 years is superior to having
a prosthesis for 25 years.
As far as survival in all patients, mitral valve repair does not
emerge as a factor that increases overall survival. Rather, survival is
influenced more by traditional factors, including left ventricular dys-
function, advanced age, and other comorbidities. I amnot sure thatwe
will ever be able to do a prospective study that directly addresses the
survival impact of mitral valve repair when compared with replace-
ment. It is currently not feasible to take 57-year-old people with pos-
terior leaflet prolapse and randomize them to our best prosthesis or our
best repair. So we are just going to have to come at that question from
as many directions as possible using existing data.
Dr Irving Kron (Charlottesville, Va). I am fearful that the mes-
sage will be misinterpreted, and I am sure you have thought about
this. Certainly at the Cleveland Clinic you are going to do everything
you can to repair a valve. Literally less than 10% of your valves were
replaced. So the typical patient who undergoes replacement in the
United States probably has bileaflet prolapse and is younger. You
didn’t show us that group, but my suspicion would be, and certainly
our bias is, that they should be repaired. What are your thoughts
about this?
Dr Gillinov.We agree. The first thing Dr Lytle said to me about
this topic was to be careful in framing the message of this article be-
cause a reader may look at the title, draw a conclusion about mitral
valve repair, and stop there. We have carefully tried to craft the mes-
sage and point out that in the patient you have described, who is
younger with bileaflet prolapse, we would strive to repair that valve.
In addition, we repair most degenerative valves in elderly patients.
This article focuses primarily on the elderly patients with complex
pathology, the group who did have enough replacements to enable
comparison between repair and replacement.
Dr Thierry Mesana (Ottawa, Ontario, Canada). Did you see
any difference in mortality in your 2 subsets of patients, and have
you changed your policies in your institution in relation to this
study? For example, what do you do when you have a posterior leaf-
let prolapse with a moderate level of calcification in a patient aged
80 years or more?ril 2008
Gillinov et al Surgery for Acquired Cardiovascular DiseaseDr Gillinov. Let me answer the second question first, and this
relates to the many different combinations of valvular pathology.
If the valve looks repairable, we repair it, whether there is calcium,
bileaflet prolapse, or anterior leaflet prolapse. If we can repair the
valve, we do so. As far as mortality, I think that was one of the
key messages I tried to get across. Overall, repair looks better, but
when you compare matched patients, repair and replacement are
similar; but those matched patients are older and sicker, with more
complex conditions, and this message may not be generalizable to
the typical young patients undergoing repair.
Dr David Adams (New York, NY). In your propensity-matched
repairs, did calcium and bileaflet prolapse influence the success and
durability of the repair over time? In other words, your repair group
had calcification and bileaflet prolapse. Can you give us a sense that
these repairs were durable and that you actually solved their regur-
gitation over time?
DrGillinov. I thinkwhat you are suggesting is the possibility that
the matched patients undergoing repair did not do well because the
repairs were not as good or as durable as more straightforward re-
pairs.Wedid not look closely at durability in this study except to state
that the reoperation rate, which is a crude estimate of durability, was
similar after repair and replacement. Other studies (eg, Dr David’s
own study looking at bileaflet vs anterior and posterior leaflet pro-
lapse) demonstrate good durability with the complex repairs but
not as good as the durability with a standard P2 prolapse. Therefore,
it is possible that reduced durability in complex patients may influ-
ence survival. However, statistically it is challenging to determine
the relationship between 2 different outcomes of an intervention, re-
pair durability and survival both being outcomes of the operation.
Dr Christoph Knosalla (Berlin, Germany). Because preserva-
tion of the subvalvular apparatus is also important after mitral valve
replacement, I am wondering how and to what extent this has been
achieved in the patients you operated on?
Dr Gillinov. That is a good question. In this cohort, virtually all
of the patients undergoing replacement had preservation of the pos-
terior leaflet and the subvalvular apparatus, but preservation of the
anterior leaflet was less common.
Dr John Conte (Baltimore, Md). Many of us have been willing
to accept less than perfect results for repairs in some patients because
we have truly believed that repair was better. Do you think what youThe Journal of Thmay have done, and some people may interpret the results of this ar-
ticle as such, is raised the bar for what is acceptable as a repair in
a 70-year-old patient? So we might not accept a less than perfect re-
pair in a 70-year-old patient. We might in fact use a biological valve
as replacement. Your comments on that, please.
Dr Gillinov. Well, our data do not let us answer that question,
but I will speculate. I think a good replacement is better than
a bad repair, and I would not accept a bad repair, especially in some-
body who is elderly. A good replacement is superior to a bad repair.
Dr Francis C. Wells (Cambridge, UK). As the self-help philos-
opher always says, the glass is either half full or half empty, and you
can look at your results in another way and say that you have
achieved considerably good results in a difficult group of patients.
Have you had a chance to dissect out in greater detail what you
were doing in the repair group in the older, sicker, more calcified
group? Because to actually match a valve that is designed to be com-
petent ‘‘off the blocks,’’ as it were, to have the same results in that
difficult group is quite an achievement.
Dr Gillinov. We have looked at these patients in greater detail.
Among older patients with more complex valves, the majority re-
ceived a repair. The durability of these repairs is acceptable, but
not as good as durability after a standard posterior leaflet resection.
If you are going to repair these valves, you need to have a good re-
pair at the end of the day. Therefore, we leave the operating room
with a selected group of patients; we leave with the ones who had
a good repair confirmed by intraoperative transesophageal echocar-
diography. There were some patients in this series who had an at-
tempt at repair, it failed, and they left with a replacement, and I
think that that is okay, too, as long as they leave the operating
room with a mitral valve that works.
Dr Bruce Lytle (Cleveland, Ohio). What is important to re-
member, though, is that this is a setting where surgeons believe
in mitral valve repair and repair 90% of the valves in any kind of
patient with degenerative valve disease who comes in, and within
that setting, for that 10% of patients with complications and comor-
bidities, for whatever reason the valve is not repaired, it does not
seem to compromise survival. We are talking about 10% of patients
with degenerative valve disease at that extreme end of being diffi-
cult to repair. I think it is important we not lose sight of that. So
this is a small group.oracic and Cardiovascular Surgery c Volume 135, Number 4 893
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Risk factor Coefficient 6 SE P Reliability (%)*
Early hazard phase
MV replacement 0.41 6 0.47 .4 –
Failed MV repair attempt 0.27 6 0.60 .6 –
Propensity for replacement 0.57 6 0.74 .4 –
Older agey 0.85 6 0.21 ,.0001 97
History of heart failure 1.05 6 0.34 .002 66
LV ejection fraction 20.043 6 0.015 .003 71
Earlier date of operationz 0.092 6 0.029 .001 64
Late hazard phase
MV replacement 0.047 6 0.24 .8 –
Failed MV repair attempt 20.23 6 0.38 .5 –
Propensity for replacement 0.88 6 0.38 .02 –
Older agex 5.83 6 0.81 ,.0001 100
NYHA class III or IV 0.36 6 0.14 .01 90
LV dysfunction (echo grade) 0.33 6 0.099 .0009 85
Elevated bilirubink 0.41 6 0.14 .003 61
History of renal disease 0.90 6 0.35 .01 60
Calcified MV 0.33 6 0.14 .02 62
Cleft MV leaflet 1.17 6 0.41 .005 59
LV, Left ventricular;MV,mitral valve;NYHA,New York Heart Association; SE, standard error. No reliable factors were found in constant hazard phase. *Percent
of occurrences in 200 bootstrap models. yExp (age/50 y), exponential transformation. zInterval: (1/d from 1/1/85 to operation)2, inverse squared transformation.
xLn (age), logarithmic transformation. kLn (bilirubin), logarithmic transformation.A
CD
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